110 related articles for article (PubMed ID: 18349417)
1. Human epidermal growth factor receptor 2 testing in breast cancer: 30% versus 10% cutoff for immunohistochemistry.
Hameed O; Chhieng D; Adams AL
J Clin Oncol; 2008 Mar; 26(9):1571. PubMed ID: 18349417
[No Abstract] [Full Text] [Related]
2. Human epidermal growth factor receptor 2 testing in breast cancer.
Vang Nielsen K; Jørgensen JT; Schønau A; Øster A
J Clin Oncol; 2007 Sep; 25(25):4020; author reply 4021-3. PubMed ID: 17761991
[No Abstract] [Full Text] [Related]
3. Human epidermal growth factor receptor 2 testing recommendation.
Raji A
J Clin Oncol; 2007 Sep; 25(25):4020-1; author reply 4021-3. PubMed ID: 17761990
[No Abstract] [Full Text] [Related]
4. HER2 testing: current status and future directions.
Perez EA; Cortés J; Gonzalez-Angulo AM; Bartlett JM
Cancer Treat Rev; 2014 Mar; 40(2):276-84. PubMed ID: 24080154
[TBL] [Abstract][Full Text] [Related]
5. Lapatinib study supports cancer stem cell hypothesis, encourages industry research.
Schmidt C
J Natl Cancer Inst; 2008 May; 100(10):694-5. PubMed ID: 18477795
[No Abstract] [Full Text] [Related]
6. Increased risk of brain metastases in patients with HER-2/neu-positive breast carcinoma.
Altaha R; Crowell E; Hobbs G; Higa G; Abraham J
Cancer; 2005 Feb; 103(3):442-3. PubMed ID: 15578684
[No Abstract] [Full Text] [Related]
7. Clinical significance of basal-like subtype in triple-negative breast cancer.
Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer testing scandal shines spotlight on black box of clinical laboratory testing.
Hede K
J Natl Cancer Inst; 2008 Jun; 100(12):836-7, 844. PubMed ID: 18544732
[No Abstract] [Full Text] [Related]
9. Clinical practice patterns and cost-effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients.
Fitzgibbons P; Washington MK; Murphy D
Cancer; 2010 Aug; 116(16):3980-1; author reply 3981. PubMed ID: 20564109
[No Abstract] [Full Text] [Related]
10. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
Rhee J; Han SW; Oh DY; Kim JH; Im SA; Han W; Park IA; Noh DY; Bang YJ; Kim TY
BMC Cancer; 2008 Oct; 8():307. PubMed ID: 18947390
[TBL] [Abstract][Full Text] [Related]
11. Current status of HER2 testing: caught between a rock and a hard place.
Schnitt SJ; Jacobs TW
Am J Clin Pathol; 2001 Dec; 116(6):806-10. PubMed ID: 11764067
[No Abstract] [Full Text] [Related]
12. Immunohistochemical detection of EGFR, p185(erbB-2), Bcl-2 and p53 in breast carcinomas in pre-menopausal and post-menopausal women.
Talley L; Chhieng DC; Bell WC; Grizzle WE; Frost AR
Biotech Histochem; 2008 Feb; 83(1):5-14. PubMed ID: 18568671
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant therapy for breast cancer.
Atkins CD
N Engl J Med; 1994 Sep; 331(11):744; author reply 745-6. PubMed ID: 7914676
[No Abstract] [Full Text] [Related]
14. Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice.
Egervari K; Szollosi Z; Nemes Z; Kaczur V
Am J Clin Pathol; 2006 Jan; 125(1):155-6. PubMed ID: 16483004
[No Abstract] [Full Text] [Related]
15. Increased expression of osteopontin in patients with triple-negative breast cancer.
Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J
Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545
[TBL] [Abstract][Full Text] [Related]
16. [Biological features of breast cancer in patients under 35].
Damenia AO; Turkevich EA; Semiglazov VF; Kochetova IA; Gurbanov SS; Bit-Sava EM; Efimenko AV
Vopr Onkol; 2007; 53(6):674-6. PubMed ID: 18416136
[TBL] [Abstract][Full Text] [Related]
17. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E
Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215
[TBL] [Abstract][Full Text] [Related]
18. Re: How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear.
Moelans CB; van Diest PJ
J Natl Cancer Inst; 2011 Apr; 103(8):698-9. PubMed ID: 21406657
[No Abstract] [Full Text] [Related]
19. Does using a higher cutoff for the percentage of positive cells improve the specificity of HER-2 immunohistochemical analysis in breast carcinoma?
Hameed O; Chhieng DC; Adams AL
Am J Clin Pathol; 2007 Nov; 128(5):825-9. PubMed ID: 17951206
[TBL] [Abstract][Full Text] [Related]
20. Triple negative, basal cell type and EGFR positive invasive breast carcinoma in Kuwaiti and British patients.
Ayad E; Francis I; Peston D; Shousha S
Breast J; 2009; 15(1):109-11. PubMed ID: 19077133
[No Abstract] [Full Text] [Related]
[Next] [New Search]